PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy

Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation in the past two decades as a promising molecular target for prostate cancer (PCa). Its appealing molecular features have enabled the development of a novel diagnostic and therapeutic—thus “theranostic”—approach...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 12; no. 6; p. 1367
Main Authors Jones, Wallace, Griffiths, Kelly, Barata, Pedro C., Paller, Channing J.
Format Journal Article
LanguageEnglish
Published Switzerland MDPI 26.05.2020
Subjects
Review
theranostics
prostate cancer
prostate specific membrane antigen
Online AccessGet full text

Cover

More Information
Summary:Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation in the past two decades as a promising molecular target for prostate cancer (PCa). Its appealing molecular features have enabled the development of a novel diagnostic and therapeutic—thus “theranostic”—approach to PCa. There is now substantial evidence of the high sensitivity of PSMA-targeted imaging for PCa lesions and growing evidence of the therapeutic efficacy of PSMA radioligand therapy for metastatic castration-resistant prostate cancer. This article presents a broad overview of the current status of PSMA theranostics, including current evidence, potential clinical impact, and active areas of research.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Denotes equal contribution.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12061367